Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer

July 15th 2014

The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Monk on Bevacizumab in Recurrent Cervical Cancer

July 14th 2014

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the utility of bevacizumab in recurrent cervical cancer.

HPV-Targeting Immunotherapy Shows Early Promise in Cervical Cancer

June 2nd 2014

Two patients with metastatic cervical cancer achieved durable complete responses that have so far lasted from 15 to 22 months through an adoptive T-cell therapy (ACT) targeting the human papillomavirus (HPV) in a study that researchers say supports the concept that the experimental immunotherapy approach may be beneficial in a variety of tumor types.

Study Suggests More Than Two-Thirds of Healthy Americans Are Infected with Human Papilloma Viruses

May 28th 2014

Only a Few of More Than 109 Detected Strains Known to Cause Cancer

HPV Test With Genotyping Tops Cervical Cancer Screening Strategies

May 27th 2014

Cervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.

For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality

May 14th 2014

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

FDA Approves First HPV Test for Primary Cervical Cancer Screening

April 24th 2014

The FDA has approved the cobas HPV Test as a first-line screening tool for cervical cancer in women 25 and older, making it the first-ever approval for a diagnostic alternative to Pap smear.

Angiogenesis-Targeting Agents Poised to Become a Mainstay of Gynecologic Cancer Treatment

January 3rd 2014

Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.

Dr. Monk on Bevacizumab in Cervical Cancer

December 31st 2013

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

No Survival Benefit Found in LRT for Women Presenting With Metastatic Breast Cancer

December 13th 2013

In women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS),

Dr. Monk Discusses the TRINOVA-1 Trial

November 20th 2013

Bradley J. Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the TRINOVA-1 trial.

Immunotherapy Examined as Treatment Option in Locally Advanced Cervical Cancer

November 5th 2013

The notion of commandeering the immune system to treat cancer actually dates back more than a century with intratumoral bacterial injections to try and elicit tumor regression.

Dr. Schilder on PARP Inhibitors in Gynecologic Cancers

October 22nd 2013

Russell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses PARP inhibitors and their potential role in gynecologic cancers.

Dr. Morgan on Robotic Surgery in Gynecologic Cancer

October 11th 2013

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses the role of robotic surgery in gynecologic cancer.

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

October 11th 2013

For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.

Alvarez Plays Leadership Role in Gynecologic Cancer Field

September 20th 2013

Whether it involves the minutiae of preclinical studies or the broad perspective of group leadership, if the work concerns gynecologic oncology, Ronald D. Alvarez, MD, has likely tried it.

Promoting HPV Vaccination for Girls and Boys

September 10th 2013

Oncology nurses can lead the way in efforts to protect the next generation from this type of cancer if they know the facts about HPV vaccination for both girls and boys

Integrating Genetics and Genomics in GYN Patient Navigation

July 11th 2013

Cancer centers are beginning to establish oncology nurse navigator programs with integrated processes for assessment, identification, referral, education, care, and support for patients whose gynecologic cancers may be genetically-based.

Electra D. Paskett, PhD, on Cervical Cancer Screening

July 9th 2013

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.